<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839319</url>
  </required_header>
  <id_info>
    <org_study_id>27158-D</org_study_id>
    <secondary_id>U54HD012629</secondary_id>
    <nct_id>NCT00839319</nct_id>
  </id_info>
  <brief_title>HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone</brief_title>
  <acronym>HOP-3</acronym>
  <official_title>Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (Short Title (HOP-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigational study is to determine how much male hormone,
      testosterone, is necessary to maintain sperm production in the testis. This knowledge will be
      used to help in the development of a safe male hormonal contraception.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three study drugs will be used in this study: Testim (testosterone gel), Human Chorionic
      Gonadotropin (hCG) and acyline. Testosterone is a naturally occurring hormone in men. When
      given to normal men, testosterone gel will temporarily lower the amount of testosterone in
      the testes and lower sperm counts. hCG is a female hormone produced during pregnancy that is
      similar to and has the same actions as a male hormone, luteinizing hormone (LH). Like LH, hCG
      stimulates the testis to produce testosterone and sperm, and is used in the treatment of men
      who are deficient in LH. When hCG is given together with testosterone to normal men, the
      amount of testosterone in the testes will change, dependent on the amount of hCG received.
      Some participants will receive placebo hCG injections (no active medication).

      Acyline suppresses LH (luteinizing hormone) and FSH (follicle stimulating hormone), which are
      hormones made by the pituitary gland in the brain, thus blocking the signal from the brain
      that causes the testes to make testosterone. Therefore, acyline blocks testosterone
      production. Men may experience some side effects from the low levels of testosterone caused
      by acyline.

      Acyline is an experimental drug. Testosterone gel and hCG are approved for use in men with
      low testosterone levels. The U.S. Food and Drug Administration (FDA) allows testosterone gel,
      hCG and acyline to be given in combination for research to a small number of volunteers. Over
      125 men have received acyline. Both Acyline and hCG will be given by injection. Acyline
      injections are formulated by subjects weight and may be given in multiple injections.

      Participation will last approximately 2 months. The study involves a minimum of 9 visits in
      Seattle, WA. Clinic visits at Screening, Day 1 and Day 10 will take about 1-1.5 hours each.
      On Day 1 &amp; 10 a fine needle aspiration of one testis will be performed. The Day 7, Day 17,
      and Day 40 visits will take approximately 30 minutes. The other visits will take about 15
      minutes each time. Over the course of the study, which includes 5 separate blood draws,
      approximately 12 ounces (one and a half cups) of blood will be drawn. Some of the study drugs
      will be given by injection. One drug is a topical gel.

      This is NOT a trial of a male contraceptive, and the study medications will not prevent
      pregnancy. Subjects must use an acceptable form of birth control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Testosterone (T)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Luteinizing Hormone (LH)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intratesticular Testosterone (ITT-T)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>Acyline plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline plus 15 IU hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline plus 60 IU hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline plus 125 IU hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline plus Testosterone gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>300 ug/kg subcutaneous injections on Day 1.</description>
    <arm_group_label>Acyline plus Placebo</arm_group_label>
    <arm_group_label>Acyline plus 15 IU hCG</arm_group_label>
    <arm_group_label>Acyline plus 60 IU hCG</arm_group_label>
    <arm_group_label>Acyline plus 125 IU hCG</arm_group_label>
    <arm_group_label>Acyline plus Testosterone gel</arm_group_label>
    <other_name>Acyline GhRH antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo hCG (no active ingredient)</intervention_name>
    <description>placebo hCG</description>
    <arm_group_label>Acyline plus Placebo</arm_group_label>
    <other_name>placebo drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG (human chorionic gonadotropin)</intervention_name>
    <description>15 IU subcutaneous injection every other day for 10 days (5 doses)</description>
    <arm_group_label>Acyline plus 15 IU hCG</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG (human chorionic gonadotropin)</intervention_name>
    <description>60 IU subcutaneous injection</description>
    <arm_group_label>Acyline plus 60 IU hCG</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG (human chorionic gonadotropin)</intervention_name>
    <description>125 IU subcutaneous injection</description>
    <arm_group_label>Acyline plus 125 IU hCG</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>75 mg testosterone gel applied transdermally for 10 days</description>
    <arm_group_label>Acyline plus Testosterone gel</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males age 18-50

          -  Normal serum testosterone, LH and FSH

          -  PSA &lt; 4.0

          -  Agrees not to donate blood or participate in another research study during the study

          -  Informed consent

          -  In general good health based on normal screening evaluation (consisting of a medical
             history, physical exam, normal sperm count, normal serum chemistry and hematology)

          -  Must be willing to use a reliable form of contraception during the study

        Exclusion Criteria:

          -  Oligospermia (sperm count &lt; 15 million/mL after 48 hours of abstinence) and/or
             abnormal motility or morphology.

          -  Participation in a long-term male contraceptive study within the past three months

          -  History of testosterone or anabolic steroid abuse in the past

          -  Poor general health with significantly abnormal blood results

          -  History of or current testicular disease

          -  History of a bleeding disorder or need for anticoagulation

          -  History of sleep apnea and/or major psychiatric problems

          -  BMI &gt; 32

          -  Subjects with a skin condition that might interfere or be exacerbated by testosterone
             gel use

          -  Subject's with alcohol or drug use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Bremner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr</url>
    <description>Dedicated to basic and clinical research focused primarily on the male reproductive system</description>
  </link>
  <reference>
    <citation>Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9.</citation>
    <PMID>1977002</PMID>
  </reference>
  <reference>
    <citation>Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996 Mar;65(3):626-36.</citation>
    <PMID>8774299</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Zirkin BR, Santulli R, Awoniyi CA, Ewing LL. Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology. 1989 Jun;124(6):3043-9.</citation>
    <PMID>2498065</PMID>
  </reference>
  <reference>
    <citation>Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, Sutton PR, Wright WW, Brown TR, Yan X, Zirkin BR, Jarow JP. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005 May;90(5):2595-602. Epub 2005 Feb 15.</citation>
    <PMID>15713727</PMID>
  </reference>
  <reference>
    <citation>Coviello AD, Bremner WJ, Matsumoto AM, Herbst KL, Amory JK, Anawalt BD, Yan X, Brown TR, Wright WW, Zirkin BR, Jarow JP. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl. 2004 Nov-Dec;25(6):931-8.</citation>
    <PMID>15477366</PMID>
  </reference>
  <reference>
    <citation>Awoniyi CA, Sprando RL, Santulli R, Chandrashekar V, Ewing LL, Zirkin BR. Restoration of spermatogenesis by exogenously administered testosterone in rats made azoospermic by hypophysectomy or withdrawal of luteinizing hormone alone. Endocrinology. 1990 Jul;127(1):177-84.</citation>
    <PMID>2113863</PMID>
  </reference>
  <reference>
    <citation>Chen H, Chandrashekar V, Zirkin BR. Can spermatogenesis be maintained quantitatively in intact adult rats with exogenously administered dihydrotestosterone? J Androl. 1994 Mar-Apr;15(2):132-8.</citation>
    <PMID>8056636</PMID>
  </reference>
  <reference>
    <citation>Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM. Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl. 2002 Sep-Oct;23(5):684-90.</citation>
    <PMID>12185103</PMID>
  </reference>
  <results_reference>
    <citation>Roth MY, Page ST, Lin K, Anawalt BD, Matsumoto AM, Snyder CN, Marck BT, Bremner WJ, Amory JK. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab. 2010 Aug;95(8):3806-13. doi: 10.1210/jc.2010-0360. Epub 2010 May 19.</citation>
    <PMID>20484472</PMID>
  </results_reference>
  <results_reference>
    <citation>Roth MY, Lin K, Bay K, Amory JK, Anawalt BD, Matsumoto AM, Marck BT, Bremner WJ, Page ST. Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial. Fertil Steril. 2013 Jan;99(1):132-9. doi: 10.1016/j.fertnstert.2012.09.009. Epub 2012 Oct 3.</citation>
    <PMID>23040523</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <results_first_submitted>October 15, 2010</results_first_submitted>
  <results_first_submitted_qc>October 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2010</results_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>hCG</keyword>
  <keyword>testosterone</keyword>
  <keyword>Acyline</keyword>
  <keyword>Intratesticular hormone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited using rosters from prior research studies and newspaper and online advertisements.</recruitment_details>
      <pre_assignment_details>2 of 61 men decided not to enroll. 19 failed inclusion criteria, 1 withdrew consent before study procedures, 1 dropped out after Day 1, and 1 was withdrawn by the investigator for syncopal reaction. 6 did not suppress serum luteinizing hormone(affecting intratesticular testosterone)and were excluded from analysis. 31 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyline Plus Placebo</title>
          <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Acyline Plus 15 IU hCG</title>
          <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="P3">
          <title>Acyline Plus 60 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="P4">
          <title>Acyline Plus 125 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="P5">
          <title>Acyline Plus Testosterone Gel</title>
          <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">1 withdrew consent prior to procedures; 1 excluded from analysis (low serum LH)</participants>
                <participants group_id="P2" count="7">1 excluded from analysis (low serum LH)</participants>
                <participants group_id="P3" count="5">1 dropped out after Day 1 visit, 2 excluded from analysis (low serum LH)</participants>
                <participants group_id="P4" count="5">1 withdrawn by investigator for syncopal reaction , 2 excluded from analysis (low serum LH)</participants>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyline Plus Placebo</title>
          <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Acyline Plus 15 IU hCG</title>
          <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Acyline Plus 60 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="B4">
          <title>Acyline Plus 125 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="B5">
          <title>Acyline Plus Testosterone Gel</title>
          <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21" lower_limit="20" upper_limit="26"/>
                    <measurement group_id="B2" value="25" lower_limit="20" upper_limit="29"/>
                    <measurement group_id="B3" value="22" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B4" value="22" lower_limit="21" upper_limit="26"/>
                    <measurement group_id="B5" value="22" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B6" value="22" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" lower_limit="23.6" upper_limit="26.3"/>
                    <measurement group_id="B2" value="24.1" lower_limit="23.2" upper_limit="26.7"/>
                    <measurement group_id="B3" value="24.9" lower_limit="21.2" upper_limit="26.3"/>
                    <measurement group_id="B4" value="25.8" lower_limit="22.9" upper_limit="26"/>
                    <measurement group_id="B5" value="23.7" lower_limit="21.1" upper_limit="25.4"/>
                    <measurement group_id="B6" value="24.1" lower_limit="22.9" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Luteinizing Hormone (LH)</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="3.1" upper_limit="4.8"/>
                    <measurement group_id="B2" value="3.0" lower_limit="2.6" upper_limit="4.9"/>
                    <measurement group_id="B3" value="3.4" lower_limit="3.4" upper_limit="4.9"/>
                    <measurement group_id="B4" value="2.9" lower_limit="2.3" upper_limit="3.7"/>
                    <measurement group_id="B5" value="3.8" lower_limit="2.6" upper_limit="4.6"/>
                    <measurement group_id="B6" value="3.4" lower_limit="2.6" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Follicle Simulating Hormone (FSH)</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" lower_limit="1.2" upper_limit="3.4"/>
                    <measurement group_id="B2" value="2.4" lower_limit="2" upper_limit="2.8"/>
                    <measurement group_id="B3" value="2.6" lower_limit="2.2" upper_limit="3.2"/>
                    <measurement group_id="B4" value="2.2" lower_limit="1.9" upper_limit="2.5"/>
                    <measurement group_id="B5" value="1.9" lower_limit="1.3" upper_limit="2.8"/>
                    <measurement group_id="B6" value="2.4" lower_limit="1.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Testosterone (T)</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" lower_limit="11.3" upper_limit="16.9"/>
                    <measurement group_id="B2" value="15.0" lower_limit="11.4" upper_limit="20.9"/>
                    <measurement group_id="B3" value="14.2" lower_limit="12.7" upper_limit="14.9"/>
                    <measurement group_id="B4" value="16.8" lower_limit="14.4" upper_limit="18.6"/>
                    <measurement group_id="B5" value="15.0" lower_limit="13.7" upper_limit="18.3"/>
                    <measurement group_id="B6" value="14.6" lower_limit="12" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Dihydrotestosterone (DHT)</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" lower_limit="0.7" upper_limit="1.5"/>
                    <measurement group_id="B2" value="1.3" lower_limit="0.9" upper_limit="1.7"/>
                    <measurement group_id="B3" value="1.2" lower_limit="1" upper_limit="1.3"/>
                    <measurement group_id="B4" value="0.9" lower_limit="0.7" upper_limit="1.5"/>
                    <measurement group_id="B5" value="1.1" lower_limit="1.1" upper_limit="1.2"/>
                    <measurement group_id="B6" value="1.1" lower_limit="0.9" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Estradiol</title>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89" lower_limit="47" upper_limit="150"/>
                    <measurement group_id="B2" value="65" lower_limit="34" upper_limit="125"/>
                    <measurement group_id="B3" value="62" lower_limit="48" upper_limit="78"/>
                    <measurement group_id="B4" value="77" lower_limit="44" upper_limit="95"/>
                    <measurement group_id="B5" value="86" lower_limit="54" upper_limit="95"/>
                    <measurement group_id="B6" value="77" lower_limit="46" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 17-Hydroxyprogesterone</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" lower_limit="3.8" upper_limit="7.8"/>
                    <measurement group_id="B2" value="4.9" lower_limit="4.2" upper_limit="6.5"/>
                    <measurement group_id="B3" value="5.9" lower_limit="5.1" upper_limit="7.6"/>
                    <measurement group_id="B4" value="4.3" lower_limit="4" upper_limit="4.5"/>
                    <measurement group_id="B5" value="4.6" lower_limit="3.7" upper_limit="5.4"/>
                    <measurement group_id="B6" value="4.9" lower_limit="3.9" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intratesticular Testosterone (ITT-T)</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3467" lower_limit="2508" upper_limit="3839"/>
                    <measurement group_id="B2" value="2425" lower_limit="1700" upper_limit="3380"/>
                    <measurement group_id="B3" value="1821" lower_limit="1753" upper_limit="2412"/>
                    <measurement group_id="B4" value="3502" lower_limit="2305" upper_limit="3959"/>
                    <measurement group_id="B5" value="2933" lower_limit="1527" upper_limit="3390"/>
                    <measurement group_id="B6" value="2508" lower_limit="1753" upper_limit="3502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intratesticular Dihydrotestosterone (ITT-DHT)</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" lower_limit="11.9" upper_limit="24.5"/>
                    <measurement group_id="B2" value="5.0" lower_limit="4.5" upper_limit="11"/>
                    <measurement group_id="B3" value="7.6" lower_limit="7.1" upper_limit="21.3"/>
                    <measurement group_id="B4" value="18.8" lower_limit="11.1" upper_limit="22.2"/>
                    <measurement group_id="B5" value="12.9" lower_limit="7.9" upper_limit="15.5"/>
                    <measurement group_id="B6" value="11.9" lower_limit="7.3" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone (T)</title>
        <time_frame>10 days</time_frame>
        <population>Analysis per protocol. Due to nonnormality, the data were expressed as medians and 25th and 75 percentiles. Analysis of both baseline and end of treatment hormone concentrations performed on 31 subjects who completed all study procedures and who suppressed serum LH below the lower limit of normal at end of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyline Plus Placebo</title>
            <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Acyline Plus 15 IU hCG</title>
            <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Acyline Plus 60 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Acyline Plus 125 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Acyline Plus Testosterone Gel</title>
            <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone (T)</title>
          <population>Analysis per protocol. Due to nonnormality, the data were expressed as medians and 25th and 75 percentiles. Analysis of both baseline and end of treatment hormone concentrations performed on 31 subjects who completed all study procedures and who suppressed serum LH below the lower limit of normal at end of treatment.</population>
          <units>nmol/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.35" upper_limit="0.76"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.79" upper_limit="4.9"/>
                    <measurement group_id="O3" value="3.7" lower_limit="1" upper_limit="8.5"/>
                    <measurement group_id="O4" value="8.4" lower_limit="4.9" upper_limit="11"/>
                    <measurement group_id="O5" value="16" lower_limit="13" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Correlations between serum hormone levels and IT hormones, and between IT hormones were performed on 23 subjects in 4 groups using Spearmen technique.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Luteinizing Hormone (LH)</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline Plus Placebo</title>
            <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Acyline Plus 15 IU hCG</title>
            <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Acyline Plus 60 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Acyline Plus 125 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Acyline Plus Testosterone Gel</title>
            <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Luteinizing Hormone (LH)</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.07" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.2" upper_limit="1.63"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.16" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.39" lower_limit="0.28" upper_limit="1.7"/>
                    <measurement group_id="O5" value="0.14" lower_limit="0.05" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Follicle Stimulating Hormone (FSH)</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline Plus Placebo</title>
            <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Acyline Plus 15 IU hCG</title>
            <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Acyline Plus 60 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Acyline Plus 125 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Acyline Plus Testosterone Gel</title>
            <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Follicle Stimulating Hormone (FSH)</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.17" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.41" lower_limit="0.27" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.29" lower_limit="0.24" upper_limit="1.0"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.25" upper_limit="1.1"/>
                    <measurement group_id="O5" value="0.21" lower_limit="0.18" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intratesticular Testosterone (ITT-T)</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline Plus Placebo</title>
            <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Acyline Plus 15 IU hCG</title>
            <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Acyline Plus 60 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O4">
            <title>Acyline Plus 125 IU hCG</title>
            <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
          </group>
          <group group_id="O5">
            <title>Acyline Plus Testosterone Gel</title>
            <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Intratesticular Testosterone (ITT-T)</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="40" upper_limit="223"/>
                    <measurement group_id="O2" value="136" lower_limit="79" upper_limit="258"/>
                    <measurement group_id="O3" value="319" lower_limit="139" upper_limit="2455"/>
                    <measurement group_id="O4" value="987" lower_limit="895" upper_limit="1250"/>
                    <measurement group_id="O5" value="73" lower_limit="34" upper_limit="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>overall study (1 year, 5 months)</time_frame>
      <desc>The first subject was screened 3/17/09; the last subject exited 8/17/10. Subjects in the study are asked about adverse events and concomitant medications at every visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acyline Plus Placebo</title>
          <description>Acyline (ACY) 300 ug/kg subcutaneous (SQ) injections on Day 1 plus SQ placebo hCG every other day(q.o.d) (5 doses) for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Acyline Plus 15 IU hCG</title>
          <description>ACY 300 ug/kg SQ on Day 1 plus SQ 15 IU hCG q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="E3">
          <title>Acyline Plus 60 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 60 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="E4">
          <title>Acyline Plus 125 IU hCG</title>
          <description>ACY 300 ug/kg SQ Day 1 + 125 IU hCG SQ q.o.d (5 doses) for 10 days</description>
        </group>
        <group group_id="E5">
          <title>Acyline Plus Testosterone Gel</title>
          <description>ACY 300 ug/kg SQ on Day 1 + Testosterone gel 75 mg/day daily for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>decreased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>fatigue for 12 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>slight dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>testicular soreness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry itchy skin</sub_title>
                <description>dry itchy skin at site of gel application</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mara Roth, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-221-0519</phone>
      <email>mylang@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

